Cargando…

Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing

INTRODUCTION: Varenicline is an effective smoking cessation medicine. However, the possible adverse neuropsychiatric events reported by Food and Drug Administration for varenicline may cause safety problems for professional drivers. We aimed to investigate its safety and impacts on driving behaviors...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Shuilian, Liang, Lirong, Jing, Hang, Zhang, Di, Tong, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID) 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263361/
https://www.ncbi.nlm.nih.gov/pubmed/32494237
http://dx.doi.org/10.18332/tid/120935
_version_ 1783540792797691904
author Chu, Shuilian
Liang, Lirong
Jing, Hang
Zhang, Di
Tong, Zhaohui
author_facet Chu, Shuilian
Liang, Lirong
Jing, Hang
Zhang, Di
Tong, Zhaohui
author_sort Chu, Shuilian
collection PubMed
description INTRODUCTION: Varenicline is an effective smoking cessation medicine. However, the possible adverse neuropsychiatric events reported by Food and Drug Administration for varenicline may cause safety problems for professional drivers. We aimed to investigate its safety and impacts on driving behaviors among taxi drivers in Beijing, China. METHODS: An observational cohort study was conducted in a smoking cessation clinic in Beijing, China, between September 2017 and April 2018. Smokers with varenicline for smoking cessation were included and categorized into taxi-driver smokers (n=103) and non-taxi-driver smokers (n=119). All participants received varenicline up to 12 weeks and five standardized counseling sessions. Treatment-related adverse events (AEs) were collected in all participants and their impacts on driving behaviors were assessed in taxi-driver smokers. Multiple logistic regression analysis was used to examine potential risk factors for vareniclinerelated somnolence/fatigue. RESULTS: The incidence of most treatment-related AEs was similar between taxi-driver smokers and non-taxi-driver smokers, but treatment-related somnolence/ fatigue was more frequently reported in taxi-driver smokers (18.4% vs 6.7%; p=0.008). Most taxi-driver smokers (87.4%) reported that treatment-related AEs did not affect their driving behaviors, and no traffic accident was reported during treatment. CONCLUSIONS: Varenicline appears to be a well-tolerated smoking cessation aid for Beijing taxi drivers and has less impact on driving behaviors. However, taxi-driver smokers were more likely to report somnolence/fatigue during varenicline treatment and physicians should pay more attention to this occupational population.
format Online
Article
Text
id pubmed-7263361
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID)
record_format MEDLINE/PubMed
spelling pubmed-72633612020-06-02 Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing Chu, Shuilian Liang, Lirong Jing, Hang Zhang, Di Tong, Zhaohui Tob Induc Dis Research Paper INTRODUCTION: Varenicline is an effective smoking cessation medicine. However, the possible adverse neuropsychiatric events reported by Food and Drug Administration for varenicline may cause safety problems for professional drivers. We aimed to investigate its safety and impacts on driving behaviors among taxi drivers in Beijing, China. METHODS: An observational cohort study was conducted in a smoking cessation clinic in Beijing, China, between September 2017 and April 2018. Smokers with varenicline for smoking cessation were included and categorized into taxi-driver smokers (n=103) and non-taxi-driver smokers (n=119). All participants received varenicline up to 12 weeks and five standardized counseling sessions. Treatment-related adverse events (AEs) were collected in all participants and their impacts on driving behaviors were assessed in taxi-driver smokers. Multiple logistic regression analysis was used to examine potential risk factors for vareniclinerelated somnolence/fatigue. RESULTS: The incidence of most treatment-related AEs was similar between taxi-driver smokers and non-taxi-driver smokers, but treatment-related somnolence/ fatigue was more frequently reported in taxi-driver smokers (18.4% vs 6.7%; p=0.008). Most taxi-driver smokers (87.4%) reported that treatment-related AEs did not affect their driving behaviors, and no traffic accident was reported during treatment. CONCLUSIONS: Varenicline appears to be a well-tolerated smoking cessation aid for Beijing taxi drivers and has less impact on driving behaviors. However, taxi-driver smokers were more likely to report somnolence/fatigue during varenicline treatment and physicians should pay more attention to this occupational population. European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID) 2020-05-27 /pmc/articles/PMC7263361/ /pubmed/32494237 http://dx.doi.org/10.18332/tid/120935 Text en © 2020 Chu S. et al. https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License.
spellingShingle Research Paper
Chu, Shuilian
Liang, Lirong
Jing, Hang
Zhang, Di
Tong, Zhaohui
Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing
title Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing
title_full Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing
title_fullStr Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing
title_full_unstemmed Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing
title_short Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing
title_sort safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: an observational cohort study of taxi drivers in beijing
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263361/
https://www.ncbi.nlm.nih.gov/pubmed/32494237
http://dx.doi.org/10.18332/tid/120935
work_keys_str_mv AT chushuilian safetyofvareniclineasanaidtosmokingcessationinprofessionaldriversanditsimpactondrivingbehaviorsanobservationalcohortstudyoftaxidriversinbeijing
AT lianglirong safetyofvareniclineasanaidtosmokingcessationinprofessionaldriversanditsimpactondrivingbehaviorsanobservationalcohortstudyoftaxidriversinbeijing
AT jinghang safetyofvareniclineasanaidtosmokingcessationinprofessionaldriversanditsimpactondrivingbehaviorsanobservationalcohortstudyoftaxidriversinbeijing
AT zhangdi safetyofvareniclineasanaidtosmokingcessationinprofessionaldriversanditsimpactondrivingbehaviorsanobservationalcohortstudyoftaxidriversinbeijing
AT tongzhaohui safetyofvareniclineasanaidtosmokingcessationinprofessionaldriversanditsimpactondrivingbehaviorsanobservationalcohortstudyoftaxidriversinbeijing